Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Feedback’s new boss sets out his stall after strategic review

Feedback’s new boss, David Crabb, has only been in the job a matter of months, but he is already making his presence felt
doctors looking at x-ray
Feedback’s TexRAD software analyses medical images to help give an accurate prognosis

The new boss of Feedback plc (LON:FDBK) has outlined his plans for the medical imaging technology group after completing a strategic review.

David Crabb was brought in back in February and, along with the new members of his executive team, has been looking at ways to simplify and streamline the AIM-listed firm.

READ: Feedback tweaks structure and board

“Our vision is to lead global innovation in quantitative medical imaging analysis, and since February 2018 I have been resolutely focused on making the necessary organisational and operational changes for long-term growth,” said Crabb.

“The new team and organisational structure will allow us to leverage our deep domain expertise to continue to build our market share.”

He added: “As with any period of change, there may be an impact on operational developments in the short-term, however all efforts are now focused on delivering the four areas of our strategy and I look forward to reporting more progress during 2018.”

Feedback told investors back in April that it was merging two of its subsidiaries – Cambridge Computed Imaging and TexRAD – into a new entity called Feedback Medical.

Crabb added on Thursday that he wants to build on the company’s “impressive” customer base by expanding into new global markets and exploring the use of the TexRAD technology in the pharma industry.

Develop TexRAD and Cadran platforms

TexRAD Lung – a piece of software that analyses medical images of lung lesions – is Feedback’s most advanced product.

Three major UK hospitals are currently trialling it, after which the company will build in any modifications they suggest and then market it properly to its existing customer base. The plan is to also develop TexRAD for use in other indications.

Feedback’s time and money has generally been directed toward TexRAD, but Crabb wants to devote more resources towards the firm’s Cadran medical imaging technology platform.

Cadran has a lot of competition from expensive rivals, but the company wants to target developing countries and other global markets which might be interested in a more cost-effective option.

View full FDBK profile View Profile

Feedback plc Timeline

Related Articles

Hydrogen refuelling
April 05 2018
As the move towards alternative fuels for vehicles gathers pace, news last month of the opening of the first 'under the canopy' hydrogen refuelling station at Beaconsfield Services on the M40 deserved a bit of a fanfare
Medical Scan
August 03 2018
TexRAD is essentially a very smart piece of software that analyses medical images to reveal features that are not always evident to the human eye
Light fittings
August 23 2018
The group's traditional LED business is operating in a fiercely competitive environment. The group is pinning its hopes on becoming a software and services business

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use